DIRS.INFO The most relevant business & tech news

☆ AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'
▼ + stars: | 2024-05-21 | by ( Sophie Kiderlin | In | ) www.cnbc.com time to read: +2 min

Costfoto | Future Publishing | Getty ImagesLONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and expects to release an additional 20 medicines in the next six years. "Many of them have the potential to be $5 billion drugs," Sarin noted. A company statement detailed that this revenue figure could be hit annually for many of the new medicines in peak years. "For the entire market to get replaced it will take time, but we think we have the technology today to start replacing them," Sarin told CNBC.

Persons: CNBC's Arabile Gumede Organizations: Astrazeneca, Artificial Intelligence, — Pharmaceutical, AstraZeneca, CNBC, U.S . FDA, Pharmaceuticals, Investments Locations: Shanghai, China, Europe, London, Singapore

☆ Daiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'
▼ + stars: | 2024-04-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDaiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'Hiroyuki Okuzawa, president and COO of the Japanese pharma company, discusses the company's results and growth projections.

Persons: Hiroyuki Okuzawa Organizations: Japanese pharma

☆ Stocks making the biggest moves premarket: Qualcomm, Merck, General Motors and more
▼ + stars: | 2024-02-01 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

The stock is trading at a low multiple compared to spending, the firm highlighted as a key catalyst for investors. Nextracker — Shares of the solar technology company jumped 17% on bullish analyst notes following its strong quarterly results and guidance increase. Wolfspeed guided for fiscal third-quarter revenue of $185 million to $215 million, below the $224 million, LSEG estimate. Robinson reported 50 cents per share in adjusted earnings, while analysts expected 81 cents per share, per LSEG. The company reported $9.44 billion in revenue, while analysts surveyed by LSEG were looking for $9.70 billion.

Persons: Christopher Danely, Morgan Stanley, Nextracker, Wolfspeed, TD Cowen, ChargePoint, C.H, Robinson, Merck, company's, —, Alex Harring, Lisa Kailai Han, Tanaya Macheel, Jesse Pound, Michelle Fox Theobald Organizations: Qualcomm, Citi, General Motors, General, Barclays, Bank of America, Revenue, Merck, Japanese, Honeywell, LSEG, Norfolk Southern, Ancora Holdings, Wall Street Journal Locations: Norfolk Southern

☆ Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
▼ + stars: | 2024-02-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. Excluding acquisition and restructuring costs, Merck earned 3 cents per share for the fourth quarter. Merck raked in $14.63 billion in revenue for the quarter, up 6% from the same period a year ago. Analysts surveyed by LSEG expected Merck to forecast full-year sales of $63.52 billion and adjusted earnings of $8.42 per share. Merck recorded charges of $190 million related to the program in the fourth quarter, which is excluded from its adjusted results.

Persons: Merck Organizations: Merck & Co, New York Stock Exchange, Merck, LSEG, Harpoon Therapeutics Locations: New York City , New York, U.S

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Japan takes earthquake safety seriously. Here's how its culture of preparedness keeps so many people alive.
▼ + stars: | 2024-01-05 | by ( Jenny Mcgrath | Morgan Mcfall-Johnsen | ) www.businessinsider.com time to read: +10 min

With its history of natural disasters, Japan is one of the countries best prepared for emergencies. Japan now has some of the strictest building codes of any country in the world, The New York Times reported after the 2011 earthquake. Japan installs resilient infrastructureMuch like its buildings, Japan has the experience and the money to fortify its infrastructure against earthquakes. During that 2011 disaster, rapid response teams were able to quickly repair roads to help move supplies and assistance to affected areas. According to the World Bank, historical knowledge may have helped save lives during Japan's 2011 tsunami.

Persons: —, Daniel Aldrich, Aldrich, he's, Kim Kyung, They're Organizations: Service, Reuters, World Bank, Northeastern University, Japan, New York Times, BBC News, Officials, Universal Studios Japan, Kyodo, REUTERS, Japan Meteorological Society, Japan Railways, Japan Times, Guardian, KYODO, Japan Meteorological Agency, NOAA Locations: Japan, Noto, Turkey, Syria, Haiti, Pakistan, Wajima, Tokyo, Mashiki, Kumamoto, Fukushima, Natori

☆ Satellite photos of earthquakes in Japan in 2024 and 2011 show the destruction each left in its aftermath
▼ + stars: | 2024-01-04 | by ( Jenny Mcgrath | ) www.businessinsider.com time to read: +5 min

Satellite image ©2024 Maxar TechnologiesDuring the 2024 earthquake, buildings and homes were leveled in Wajima. Satellite image ©2024 Maxar TechnologiesBoats capsized off the coast of Suzu City when the 2024 earthquake hit. Satellite image ©2024 Maxar Technologies. Satellite image ©2024 Maxar TechnologiesRoads cracked open as a result of the 2024 earthquake. ASSOCIATED PRESS (left) / Satellite image ©2024 Maxar Technologies (right)The total death toll and overall destruction from the 2024 quake are still unclear as rescuers scramble to save people trapped under rubble.

Persons: —, it's, Suzu's, Masuhiro Izumiya Organizations: Service, Japan Meteorological Agency, Fukushima, International Tsunami Information, Ministry of Foreign Affairs of Japan, National Oceanic, Atmospheric Administration, BBC, Guardian, Technologies, Washington Post, Japan Times, AP News Locations: Japan, Noto Peninsula, Sendai, Ishinomaki, Natori Port, Fukushima, Wajima, Suzu City, Noto, Suzu, Turkey

☆ China's bragging about being the first to build a next-generation nuclear reactor. Here's how it compares to reactors in countries like the US, Japan, and Russia.
▼ + stars: | 2023-12-07 | by ( Matthew Loh | ) www.businessinsider.com time to read: +3 min

China on Wednesday said the Shidaowan nuclear reactor is officially contributing to the power grid. AdvertisementChina on Wednesday announced that it's started commercial operations at the world's first next-generation nuclear reactor. AdvertisementThe Fukushima plant in Japan had six reactors producing 4.69 gigawatts, while Russia's BN-1200 reactor in Beloyarsk produces 1,200 megawatts. But it's already missed its 2020 target of producing 58 gigawatts with nuclear reactors, instead producing 53 gigawatts. Nuclear reactors in the US can generate up to 95.86 gigawatts of electricity, per the IAEA.

Persons: —, it's, It's Organizations: Service, Wednesday, Tsinghua University, China National Nuclear Corporation, National Energy Administration, Russia's, Xinhua, International Atomic Energy Agency, US, Nuclear Locations: China, Shandong, Port Gibson , Mississippi, Japan, Beloyarsk, Oarai, Fukushima, India

☆ Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which are designed to directly kill cancer cells and spare healthy ones. Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout. The SPDR S&P Biotech ETF , which focuses on small and midsize biotech companies, rose 3% Thursday. Under the terms of the deal, AbbVie will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday's closing price.

Persons: AbbVie, ImmunoGen, Michael Schmidt Organizations: Biotech, Mersana Therapeutics, ADC Therapeutics, P Biotech ETF, Nasdaq Biotechnology, ImmunoGen, Pfizer, Merck, CNBC PRO Locations: ADCs

☆ AbbVie to buy cancer drugmaker ImmunoGen for $10 billion as Humira faces heat
▼ + stars: | 2023-11-30 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Brian Snyder/File Photo Acquire Licensing RightsNov 30 (Reuters) - AbbVie (ABBV.N) will buy ImmunoGen (IMGN.O) for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to buy a developer of 'guided missile' cancer therapies as the company's top-seller Humira grapples with fierce competition. ImmunoGen's Elahere belongs to a new class of treatments called antibody-drug conjugates (ADC) that precisely targets cancer cells, potentially reducing toxicity for other cells. The drug, approved for ovarian cancer patients who have received previous therapies, is also being tested in earlier lines of treatment. AbbVie will also get access to Immunogen's follow-on pipeline of ADCs, including early-stage ovarian cancer candidate IMGN-151 and a mid-stage drug pivekimab sunirine for a rare type of blood cancer. Meanwhile, AbbVie's cancer drugs sales declined more than 8% in the third quarter to $1.51 billion, primarily due to increased competition to Imbruvica.

Persons: Brian Snyder, ImmunoGen's Elahere, AbbVie, IMGN, pivekimab, Immuogen stock's, Immunogen's, Elahere, Imbruvica, Manas Mishra, Leroy Leo, Shinjini Ganguli Organizations: REUTERS, Pfizer, Merck, U.S, Thomson Locations: Cambridge , Massachusetts, U.S, Bengaluru

Souring relations between Asian rivals Japan and China now seem to be snagged on calm-inducing beauty in spas, museums and gardens. In recent years, koi have become hugely popular in Asia, with Japan's koi exports doubling over the past decade to 6.3 billion yen ($43 million) — one-fifth of them shipped to China, the top Japanese koi importer, followed by the United States and Indonesia. Fisheries Agency official Satoru Abe, in charge of koi quarantine, said China has not provided any explanation as to why it hasn't taken the necessary steps to continue koi shipments. IS THIS RELATED TO FUKUSHIMA DAIICHI'S TREATED WASTEWATER RELEASE? Abe, the koi quarantine official, said Fukushima’s wastewater release is unlikely to be the cause of the koi export stoppage, noting that China allowed Japanese koi in for two months after the water discharge began.

Persons: Satoru Abe, Abe, Ichiro Miyashita, “, Hirokazu Matsuno Organizations: TOKYO, CHINA, Japan . Fisheries Agency, International Atomic Energy Agency, Forestry, Fisheries Locations: Japan, China, Asia, United States, Indonesia, Beijing, Tokyo, JAPAN, CHINA, East China

TOKYO (AP) — The tsunami-damaged Fukushima Daiichi nuclear power plant began its third release of treated and diluted radioactive wastewater into the sea Thursday after Japanese officials said the two earlier releases ended smoothly. The plant operator discharged 7,800 tons of treated water in each of the first two batches and plans to release the same amount in the current batch through Nov. 20. The plant began the first wastewater release in August and will continue to do so for decades. About 1.34 million tons of radioactive wastewater is stored in about 1,000 tanks at the plant. China immediately banned all imports of Japanese seafood, badly hurting Japanese seafood producers and exporters.

Organizations: TOKYO, Tokyo Electric Power Company Holdings, TEPCO, Health, International Atomic Energy Agency, IAEA Locations: Japan, South Korea, China, Asia, asia

“After China's ban on Japanese seafood, we are seeing more customers buying not only Fukushima fish but also Japanese seafood in general to support the industry." Despite the wastewater discharges, auction prices at Fukushima fish markets have remained stable — or even occasionally higher than normal. While individual consumers favor ordering fish by mail and shopping at seafood markets, prefectural government cafeterias have started serving Fukushima seafood for lunch. In Kyoto, a group of world-renowned Japanese “Kaiseki” cuisine chefs, will develop menus that primarily use Fukushima fish starting early next year. “I wish I could sell more local fish,” Haga said.

Persons: Kazuto Harada, “, ”, “ I'm, it’s, Futoshi Kinoshita, Katsuya Goto, ” Goto, Yoshinori Tanaka, ” Tanaka, Haga, ” Haga Organizations: —, International Atomic Energy Agency, IAEA, Tokyo Electric Power Company, United States Embassy, TEPCO, Tokyo Metropolitan Government, Japanese Culinary Academy Locations: IWAKI, Japan, Onahama, Fukushima, Ibaraki, Tokyo, South Korea, Beijing, China, Kyoto, Toriyone, Asia, asia

☆ ‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon
▼ + stars: | 2023-10-26 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential antibody-drug conjugates in a deal worth up to $22 billion. Photo: Christopher Occhicone/Bloomberg NewsA true home run in the drug industry is when a company develops a mega-blockbuster that transforms its finances for years. But with Medicare trying to bring costs down by targeting the industry’s most expensive drugs, a portfolio of medium-size moneymakers that can keep your name off the U.S. government’s naughty list can be a wise strategy.

Persons: Christopher Occhicone Organizations: Merck, Bloomberg

TOKYO (AP) — Two workers at the tsunami-wrecked Fukushima Daiichi nuclear power plant were hospitalized after accidentally getting sprayed with liquid laced with radioactive materials, officials said Thursday. The incident occurred on Wednesday when a group of workers was cleaning the piping at the Advanced Liquid Processing System. The ALPS is a wastewater filtering facility that is key to the treatment of the radioactive wastewater that accumulates on the plant and its ongoing discharge into the sea. Four workers were cleaning the piping when a drainage hose suddenly came off. Political Cartoons View All 1220 ImagesTEPCO began the controversial wastewater discharges on Aug. 24 from Fukushima Daiichi, which suffered triple meltdowns following the 2011 quake and tsunami.

Persons: Junichi Matsumoto Organizations: TOKYO, Tokyo Electric Power Company Holdings, TEPCO Locations: Fukushima, China

☆ Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth
▼ + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. Merck lowered its adjusted profit guidance to $1.33 to $1.38 per share, from a previous forecast of $2.95 to $3.05 a share. But that updated outlook reflects an upfront charge of $5.5 billion, or $1.70 per share, related to the company's recent drug collaboration agreement with Daiichi Sankyo. Excluding Lagevrio, pharmaceutical sales grew 9%. The Covid antiviral treatment brought in $640 million in sales for the quarter, up 47% from the third quarter of 2022.

Persons: Merck Organizations: Merck, Prometheus Biosciences, Imago BioSciences, Kelun, Biotech, LSEG, U.S Locations: Japan, Australia

TOKYO (AP) — Japan's Prime Minister Fumio Kishida said Monday he is preparing to take bold economic measures, including an income tax cut for households hit by inflation and tax breaks for companies to promote investment, in what's seen as a move to lift his dwindling public support. “I'm determined to take unprecedentedly bold measures,” Kishida said, pledging an intensive effort to achieve stronger supply capability in about three years. “The results clearly show that many voters are dissatisfied by the government's delayed economic measures to tackle rising prices," said Jun Azumi, a senior CDPJ lawmaker. “Now is the time for me to focus on that, and I'm not thinking about anything else,” Kishida said, denying that his tax cut proposal was related to elections. The tax cuts would be part of a new economic stimulus package he plans to announce by the end of the month.

Persons: —, Fumio Kishida, Kishida, “ I'm, ” Kishida, “, ”, Azumi Organizations: TOKYO, Liberal Democratic Party, Constitutional Democratic Party of Japan Locations: what's, Nagasaki, Sunday's, Kochi, Tokushima, Ukraine, Israel, China

The announcement sent shares of Daiichi Sankyo (4568.T) up 12% in early trading in Tokyo on Friday, raising expectations for its cancer drug pipeline. The companies will jointly and potentially commercialise the drug candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights, they said. Merck will pay Daiichi Sankyo $4 billion upfront in addition to $1.5 billion in continuation payments over the next two years. Merck may make additional payments of up to $16.5 billion contingent on future sales milestones, or $5.5 billion for each product. Daiichi Sankyo has six ADC candidates in its pipeline, including two being jointly developed with AstraZeneca (AZN.L).

Persons: Andrew Kelly, Drugmaker Merck, patritumab, ifinatamab, raludotatug, Merck, David Dolan, Kanjyik Ghosh, Miyoung Kim, Jamie Freed Organizations: Merck & Co, REUTERS, Merck, AstraZeneca, Thomson Locations: Kenilworth , New Jersey, U.S, TOKYO, Daiichi, Tokyo, Japan, Bengaluru

☆ Merck’s cancer rush may spawn lower returns
▼ + stars: | 2023-10-20 | by ( ) www.reuters.com time to read: +2 min

The American drug company said on Thursday it signed a giant deal with Daiichi Sankyo (4568.T) for the rights to sell three potential drugs outside Japan. Merck will pay $4 billion upfront, up to another $1.5 billion over the next two years, and as much as $16.5 billion if the drugs pass certain sales milestones. Merck’s Keytruda accounts for about 40% of the company’s revenue, and that cancer drug might face cut-price competition before the end of the decade. The potential is giant, as these targeted therapies might eventually account for a quarter of the current oncology market. With over 100 of these drugs in clinical trials, the stampede might lead to lower-than-expected returns.

Persons: Jeff Zelevansky, Robert Cyran, Jean, Pierre Mustier, Atos, Jennifer Saba, Aditya Sriwatsav Organizations: Merck & Co, REUTERS, Reuters, Merck, Pfizer, X, News Corp, Thomson Locations: Linden , New Jersey, American, Japan

☆ India and Japan will be Asia's next power couple
▼ + stars: | 2023-10-19 | by ( Pranav Kiran | ) www.reuters.com time to read: +4 min

Indian Prime Minister Narendra Modi welcomes Japan Prime Minister Fumio Kishida upon his arrival at Bharat Mandapam convention center for the G20 Summit, in New Delhi, India, Saturday, Sept. 9, 2023. Evan Vucci/Pool via REUTERS Acquire Licensing RightsBENGALURU, Oct 19 (Reuters Breakingviews) - India and Japan are edging closer. Prime Minister Narendra Modi and Prime Minister Fumio Kishida's governments form part of the so-called Quad security grouping with the United States and Australia to counter Chinese expansionism in Asia. Now the two countries are setting up an investment fund together. That’s delivering on a pledge by Kishida to invest 5 trillion yen, or some $42 billion, into India over the next five years.

Persons: Narendra Modi, Fumio Kishida, Evan Vucci, Fumio, Kishida, Wood Mackenzie, Sajjan Jindal, India’s, Lakshmi Mittal, JBIC, Una Galani, Thomas Shum Organizations: Indian, Japan, Bharat, REUTERS Acquire, Rights, Reuters, National Investment, Infrastructure Fund, Japan Bank, International Cooperation, Japan External Trade Organization, Nippon Telegraph, Telephone, Reuters Graphics, Teck Resources, Nippon Steel, ArcelorMittal, Japan Fund, Thomson Locations: New Delhi, India, Japan, United States, Australia, Asia, Reuters Graphics India, China, Russia, South, Teck, Indian

☆ AstraZeneca shares fall as lung cancer drug trial data abstract disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after a data abstract on its experimental precision drug's use in lung cancer patients in a late-stage trial disappointed some analysts. Fernandez added that progression-free survival in lung cancer patients came in below expectations. Barclays analyst Emily Field also said in a note that safety looked better than expected for lung cancer patients and the data abstracts were "collectively positive" for AstraZeneca. London-listed shares of AstraZeneca were down 3.7% at 1219 GMT, while the broader STOXX Health Care (.SXDP) index was off 1%. Shares of AstraZeneca's Japanese partner Daiichi Sankyo (4568.T), which is jointly developing the cancer drug, closed 4.6% lower on Tuesday.

Persons: Phil Noble, datopotamab deruxtecan, Jefferies, Stephen Barker, Barker, Seamus Fernandez, Fernandez, Emily Field, GSK's, Danilo Masoni, Maggie Fick, Bhanvi, Shinjini Organizations: AstraZeneca, REUTERS, European Society for Medical, Friday, Guggeinheim, Barclays, AstraZeneca ., Thomson Locations: Macclesfield, Britain, Madrid, AstraZeneca . London, U.S, Milan, London, Bengaluru

TOKYO (AP) — Japan criticized Russia's announcement that it's joining China in banning the imports of Japanese seafood in response to the release of treated radioactive wastewater from the wrecked Fukushima nuclear power plant. China immediately banned all imports of Japanese seafood the day the release began in August, badly hurting Japanese seafood producers and exporters. The Japanese Foreign Ministry said its senior officials notified the Russian Embassy in Tokyo that Japan has been providing transparent and scientific explanations about safety of the treated water release from the Fukushima plant and Japanese seafood. “Japan continues to seek actions based on science.”The plant’s first wastewater release began Aug. 24 and ended Sept. 11. During that release, TEPCO said it discharged 7,800 tons of treated water from 10 tanks.

Persons: —, ”, “ Organizations: TOKYO, Japanese Foreign Ministry, Russian Embassy, TEPCO, International Atomic Energy Agency Locations: — Japan, China, Russia, South Korea, Russian, Tokyo, Japan, “ Japan, Canada

☆ Tepco starts releasing second batch of treated radioactive water from Fukushima nuclear plant
▼ + stars: | 2023-10-05 | by ( ) www.reuters.com time to read: +2 min

[1/3] An aerial view shows the Fukushima Daiichi nuclear power plant, which started releasing treated radioactive water into the Pacific Ocean, in Okuma town, Fukushima prefecture, Japan August 24, 2023, in this photo taken by Kyodo. Kyodo/via REUTERS/File Photo Acquire Licensing RightsTOKYO, Oct 5 (Reuters) - Tokyo Electric Power Company (9501.T) (Tepco) started releasing more treated radioactive water from the wrecked Fukushima Daiichi Nuclear Power Plant on Thursday morning, continuing a move that has caused tensions between China and Japan. Junichi Matsumoto, who is overseeing the water release at Tepco, said on Wednesday during a news conference that Tepco had received more than 6,000 calls from abroad between August 24-27. Japan started the water discharge in August in a key step towards decommissioning the Fukushima plant, which suffered meltdowns after being hit by a tsunami in 2011 in the world's worst nuclear plant disaster since Chernobyl 25 years earlier. Japan says the water is treated to remove most radioactive elements except tritium, a hydrogen isotope that must be diluted because it is difficult to filter.

Persons: Junichi Matsumoto, Matsumoto, Sakura Murakami, Gerry Doyle Organizations: Kyodo, Rights, Tokyo Electric Power Company, United Nations, Tepco, Japan, Thomson Locations: Okuma, Fukushima prefecture, Japan, China

☆ Stocks making the biggest moves in premarket trading: AstraZeneca, Paramount, Nike and more
▼ + stars: | 2023-09-25 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

AstraZeneca — Shares rose 1.4% after Jefferies upgraded the stock to buy from hold. Dow — Shares of the petrochemicals company rose 1.6% Monday during premarket trading. Chinese e-commerce stocks — U.S.-traded shares of JD.com and PDD Holdings lost 3.1% and 2.3%, respectively, as sentiment around China's economy worsened. HP — Shares of the computer company fell about 3% after Berkshire Hathaway sold 4.8 million shares, or approximately $130 million, of HP. Sealed Air — The food packaging company jumped 2.7% after Citi upgraded shares to buy from neutral.

Persons: Jefferies, Locker, Berkshire Hathaway, Anthony Pettinari, Nio, —, Alex Harring, Jesse Pound Organizations: WGA, Guild of America, SAG, Paramount Studios, AstraZeneca —, Urban Outfitters, Dow —, JPMorgan, Nike, Jefferies, Citi, U.S, PDD Holdings, Media, — Media, Paramount, Warner Bros, Disney, HP —, Berkshire, HP Locations: Los Angeles , California, China, JD.com, U.S

☆ Jefferies upgrades this pharma stock, citing overlooked 'blockbuster' drug opportunities
▼ + stars: | 2023-09-25 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

AstraZeneca's tozorakimab drug for chronic obstructive pulmonary disease also seems underappreciated, with a potential to reach $4.5 billion in peak sales, according to Jefferies. The firm also suggests up to $3.5 billion in sales for AstraZeneca's eplontersen , a drug aimed at treating hereditary transthyretin-mediated amyloid polyneuropathy. The pharmaceutical giant is also poised to be the frontrunner in breast cancer treatments. Another one of AstraZeneca's breast cancer therapies, also being developed with Daiichi Sankyo, came out with positive news Friday. Its experimental precision drug datopotamab deruxtecan demonstrated an improvement in slowing the progression of a common type of breast cancer in a late-stage trial.

Persons: Peter Welford, Welford, AstraZeneca's, Jefferies, AstraZeneca's eplontersen, transthyretin, deruxtecan, Pascal Soriot's, — CNBC's Michael Bloom Organizations: AstraZeneca, Jefferies, AstraZeneca's, Japan's, pharma Locations: Japan's Daiichi

Search resuls for: "Daiichi"

25 mentions found